Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Press Release / November 1, 2022June 3, 2024
Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events Press Release / September 15, 2022June 3, 2024
Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome Press Release / June 14, 2022June 3, 2024
Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium Uncategorized / June 8, 2022June 3, 2024
Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Myopathic Mitochondrial DNA Depletion Syndrome Press Release / May 31, 2022June 3, 2024
Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022 Press Release / May 23, 2022June 3, 2024
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy Press Release / May 12, 2022June 3, 2024
Stealth Biotherapeutics Announces Data from ReCLAIM-2 Phase 2 Trial of Elamipretide in Geographic Atrophy Press Release / May 2, 2022June 3, 2024
Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation Press Release / March 30, 2022June 3, 2024
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich’s Ataxia Press Release / March 28, 2022June 3, 2024
